| Identification | Back Directory | [Name]
1,2,4-Benzotriazin-3-aMine, 7-(2,6-dichlorophenyl)-5-Methyl-N-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- | [CAS]
867330-68-5 | [Synonyms]
1,2,4-Benzotriazin-3-aMine, 7-(2,6-dichlorophenyl)-5-Methyl-N-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- | [Molecular Formula]
C26H25Cl2N5O | [MDL Number]
MFCD24038922 | [MOL File]
867330-68-5.mol | [Molecular Weight]
494.42 |
| Hazard Information | Back Directory | [Uses]
TG-100435 is a multitargeted, orally active protein tyrosine kinase inhibitor, with Ki of 13 to 64 nM for Src, Lyn, Abl, Yes, Lck, and EphB4. TG-100435 plays an important role in cancer research[1]. | [References]
[1] Steven X Hu, et al. Metabolism and pharmacokinetics of a novel Src kinase inhibitor TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and its active N-oxide metabolite TG100855 ([7-(2,6-dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine). Comparative Study Drug Metab Dispos. 2007 Jun;35(6):929-36. DOI:10.1124/dmd.106.014290 |
|
|